CU6Clarity Pharmaceuticals Ltd

CU6 Stock Price, Valuation & Chart | Clarity Pharmaceuticals Ltd

Compare

$2.270-0.06 (-2.58%)

At close · 02 Sept 2026, 06:10 am

Sector: Healthcare Industry: Biotechnology CU6 intrinsic value CU6 calculated fair value vs price Website

Overview Financials Dividends Ratios

CU6 Historical price chart

CU6 Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization846.89M

PE Ratio-7.59

EPS-0.3

Trading Volume1.86M

Today's High/Low2.36/2.21

Dividend Yield0.00

52 Week High/Low5.87/1.8

Shares Outstanding373.08M

CU6 Financial Statement

CU6 Analyst ratings

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Based on 4 analysts giving stock ratings to CU6 in the past 3 months.

CU6 Analysis & performance metrics

CU6 Company profile

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and…

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin,…

CU6 Management team

Name

Position

Shaemus Gleason

Executive Vice President of Operations

Lisa SadetskayaCTO

Director of Corporate Communications.

David K. Green BEc., CACFO

Chief Financial Officer

Eva Lengyelova

Executive Vice President of Clinical Development

Mary Bennett

Head of People & Culture

Michelle ParkerCEO

Chief Executive Officer, MD & Executive Director

Alan John Taylor Ph.D.

Executive Chairman

Colin David Biggin Ph.D.COO

Chief Operating Officer & Non-Independent Executive Director

Name

Position

Shaemus Gleason

Executive Vice President of Operations

Lisa SadetskayaCTO

Director of Corporate Communications.

David K. Green BEc., CACFO

Chief Financial Officer

Eva Lengyelova

Executive Vice President of Clinical Development

Mary Bennett

Head of People & Culture

Michelle ParkerCEO

Chief Executive Officer, MD & Executive Director

Alan John Taylor Ph.D.

Executive Chairman

Colin David Biggin Ph.D.COO

Chief Operating Officer & Non-Independent Executive Director

Management Team

Shaemus Gleason

Executive Vice President of Operations

Lisa SadetskayaCTO

Director of Corporate Communications.

David K. Green BEc., CACFO

Chief Financial Officer

Eva Lengyelova

Executive Vice President of Clinical Development

Mary Bennett

Head of People & Culture

Michelle ParkerCEO

Chief Executive Officer, MD & Executive Director

Alan John Taylor Ph.D.

Executive Chairman

Colin David Biggin Ph.D.COO

Chief Operating Officer & Non-Independent Executive Director

Management

Shaemus Gleason

Executive Vice President of Operations

Lisa SadetskayaCTO

Director of Corporate Communications.

David K. Green BEc., CACFO

Chief Financial Officer

Eva Lengyelova

Executive Vice President of Clinical Development

Mary Bennett

Head of People & Culture

Michelle ParkerCEO

Chief Executive Officer, MD & Executive Director

Alan John Taylor Ph.D.

Executive Chairman

Colin David Biggin Ph.D.COO

Chief Operating Officer & Non-Independent Executive Director

Total 8 executives

CU6 Frequently asked questions

What is Clarity Pharmaceuticals Ltd (CU6) Stock Price?

Current stock price of Clarity Pharmaceuticals Ltd (CU6) stock is $2.270. The stock price is -2.58% lower in the session. The intraday range can be seen from this page. Volume of Clarity Pharmaceuticals Ltd (CU6) stock is 1.86M.

Last updated at 02 Sept 2026, 06:10 am.

Why is the Clarity Pharmaceuticals Ltd (CU6) stock price going up or down today?

The stock price of Clarity Pharmaceuticals Ltd (CU6) can change with earnings, company news, and overall market sentiment. Clarity Pharmaceuticals Ltd operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Clarity Pharmaceuticals Ltd stock expensive at its current price?

Whether Clarity Pharmaceuticals Ltd looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CU6 on this page is -7.59. EPS on this page is -0.30. Compare those figures with peers and growth expectations before deciding if the current Clarity Pharmaceuticals Ltd price is justified.

How has the stock price of Clarity Pharmaceuticals Ltd (CU6) performed historically?

Historical performance for Clarity Pharmaceuticals Ltd (CU6) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CU6 reacted to past earnings and market events.

Should I buy Clarity Pharmaceuticals Ltd (CU6) stock, at this price?

Buying Clarity Pharmaceuticals Ltd (CU6) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.